Document:

EX-10.21

 EXHIBIT 10.21 

Execution 4/13/06 
 THESE SECURITIES HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER
THEREOF REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 

WARRANT AGREEMENT 
 To Purchase
Shares of the Series C Preferred Stock of 
 TransOral Pharmaceuticals, Inc. 

Dated as of April 13, 2006 (the “Effective Date”)  

WHEREAS, TransOral Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has entered into a Senior Loan and Security
Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Warrantholder”); 

WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in
the Loan Agreement, the right to purchase shares of its Series C Preferred Stock pursuant to this Warrant Agreement the “Agreement”); 

NOW, THEREFORE, the Company and Warrantholder agree as follows: 
  

	1.	GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

 For value received, the Company hereby
grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, fully paid and non-assessable shares of the Preferred Stock (as
defined below) at a purchase price of $1.15 per share (the “Exercise price”). The number of Shares is equal to 5% of the aggregate Advances made under the Loan and Security Agreement dated as of the Effective Date between Company
and Warrantholder divided by the Exercise Price. The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Exchange Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation, as may be amended from time to time. 

“Common Stock” means the Company’s common stock; 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock
pursuant to a registration statement under the Act, which public offering has been declared effective by the Securities and Exchange Commission (“SEC”);  

“Merger Event” means (i) a merger or consolidation involving the Company in which the Company is not the
surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock of another entity, or (ii) the sale of all or substantially all of the assets of the
Company. 
 “Preferred Stock” means the Series C Preferred Stock of the Company and any other stock into or
for which the Series C Preferred Stock may be converted or exchanged, and upon and after the occurrences of an event which results in the automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding
shares of such Preferred Stock, including, without limitation, the consummation of an Initial Public Offering of the Common Stock in which such a conversion occurs, then from and after the date upon which such outstanding shares are so converted,
redeemed or retired, “Preferred Stock” shall mean such Common Stock; and 

 
“Purchase Price” means, with respect to any exercise of this Warrant, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of
Preferred Stock requested to be exercised under this Warrant pursuant to such exercise. 
  

	2.	TERM. 

 Except as otherwise provided for herein, the term of this Warrant and the right
to purchase Preferred Stock as granted herein (the “Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending upon the earliest to occur of (i) ten (10) years from the Effective Date; or
(ii) five (5) years after the Initial Public Offering. Notwithstanding anything herein to the contrary, upon the consummation of a Merger Event where the consideration to the Company is cash or publicly traded securities, this Warrant
shall automatically be exercised pursuant to Section 3 hereof, without any action by the holder of this Warrant. 
  

	3.	EXERCISE. 

 (a) Exercise. The purchase rights set forth in this Warrant are
exercisable by the Warrantholder, in whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached
hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed, together with payment of the Purchase Price. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance
with the terms set forth below, and in no event later than ten (10) business days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment
of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases, if any. The date which such certificate shall be deemed to
have been issued shall be the date of exercise of the Warrant in the manner set forth herein. 
 The Purchase Price may be paid at the
Warrantholder’s election either (i) by cash or check, or (ii) if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, by surrender of all or a portion of the Warrant for shares
of Preferred Stock to be exercised under this Warrant and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the
Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

									
					  X = 		Y(A-B)		
							A		
			
	Where:		X =		the number of shares of Preferred Stock to be issued to the Warrantholder.
			
			Y =		the number of shares of Preferred Stock requested to be exercised under this Warrant.
			
			A =		the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
			B =		            the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with respect to
each share of Preferred Stock: 
 (i) if the exercise is made concurrent with the closing of an Initial Public Offering, and
if the Company’s Registration Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” of the Common
Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(ii) if the exercise is after, and not in connection with, an Initial Public Offering, and: 

(1) if the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of
(x) the average of the closing prices over a five (5) trading day period ending the first 

 
trading day before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is
convertible at the time of such exercise; or 
 (2) if the Common Stock is traded over-the-counter, the fair market value
shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day trading day period ending the first trading day before the day the current fair
market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise. 

(iii) if at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or the
over-the-counter market, the current fair market value of Preferred Stock shall be the product of (x) the highest price per share which the Company could obtain from a willing buyer (not a current employee or director) for shares of Common
Stock sold by the Company, ‘from authorized but unissued shares, as most recently determined in good faith by its Board of Directors and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at
the time of such exercise, unless the exercise is made concurrent with a Merger Event pursuant to which the Company is not the surviving party, in which case the fair market value of Preferred Stock shall be deemed to be the per share value received
by the holders of the Company’s Preferred Stock on a common equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by
either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained
herein, including, but not limited to the Effective Date hereof. 
 (b) Exercise Prior to Expiration. To the extent this Warrant is
not previously exercised as to all Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed automatically exercised pursuant to
Section 3(a) (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of on share of the Preferred Stock upon such expiration shall be determined pursuant to
Section 3(a). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any,
the Warrantholder is to receive by reason of such automatic exercise. 
  

	4.	RESERVATION OF SHARES. 

 During the term of this Warrant, the Company will at all times
have authorized and reserved a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of
its Common Stock to provide for the conversion of the preferred Shares available hereunder. 
  

	5.	NO FRACTIONAL SHARES OR SCRIP. 

 No fractional shares or scrip representing fractional
shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 

 

	6.	REGISTRATION RIGHTS. 

 The holder of this Warrant shall be made a party to that certain
Amended and Restated Investor Rights Agreement (the “Investor Rights Agreement”) dated as of October 25, 2005, among the Company and the Stockholders, as defined therein, in accordance with that certain Joinder Agreement attached
hereto as Exhibit IV. 
 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Warrant. Warrantholder’s initial
address, for purposes of such registry, is set forth below Warrantholder’s signature on this Warrant. Warrantholder may change such address by giving written notice of such changed address to the Company. 

	8.	ADJUSTMENT RIGHTS. 

 The Exercise Price and the number of shares of Preferred Stock
purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger Event. Subject to the termination provisions contained in
Section 2 hereof, if at any time there shall be a Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of
shares of preferred stock or other securities or property of the successor corporation resulting from such Merger Event that would have been issuable if Warrantholder had exercised this Warrant immediately prior to the Merger Event. In any such
case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Warrantholder after the Merger
Event to the end that the provisions of this Warrant (including adjustments of the Exercise Price and number of shares of Preferred Stock purchasable) shall be applicable in their entirety, and to the greatest extent possible. Without limiting the
foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Warrant. 

(b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any time shall, by combination,
reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of securities of any other class or classes, this Warrant
shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior
to such combination, reclassification, exchange, subdivision or other change. 
 (c) Subdivision or Combination of Shares. If the
Company at any time shall combine or subdivide its Preferred Stock, (i) in the case of a subdivision, the Exercise price shall be proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Warrant
shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased, and the number of shares of Preferred Stock issuable upon the exercise of this Warrant shall be proportionately
decreased. 
 (d) Stock Dividends. If the Company at any time while this Warrant is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Preferred Stock payable in preferred Stock, then the Exercise Price shall be
adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction
(A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Preferred Stock
outstanding immediately after such dividend or distribution; or 
 (ii) make any other distribution with respect to
Preferred Stock (or stock into which the Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the
Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record
date fixed for the determination of the shareholders of the Company entitled to receive such distribution. 
 (e) Antidilution Rights.
Additional antidilution rights applicable to the preferred Stock purchasable hereunder are as set forth in the Company’s Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly
provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter that materially affects the rights of the Preferred Stock; provided, that no such amendment, modification or waiver shall impair or reduce the
antidilution rights applicable to the Preferred Stock as of the date hereof unless such amendment, modification or waiver affects the rights of Warrantholder with respect to the Preferred Stock in the same manner as it affects all other holders of
Preferred Stock. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (f), the forgoing subsection (d) and the Company’s Charter. 

(f) Notice of Adjustments. Whenever an adjustment to the Exercise price or the number of shares of Preferred Stock issuable upon
exercise of this Warrant is made pursuant to this Section 8, the Company shall send to the 

 
Warrantholder a notice setting forth, in reasonable detail, (i) the event requiring the adjustment, (ii) the amount of such adjustment, (iii) the method by which such adjustment
was calculated, (iv) the adjusted Exercise Price (if the Exercise price has been adjusted), and (v) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall cause such notice to be mailed (by
first class mail, postage. prepaid, or by reputable overnight courier with all charges prepaid) within thirty (30) days of such adjustment addressed to the Warrantholder at the address for Warrantholder set forth in the registry referred to in
Section 7. 
  

	9.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

 (a) Reservation of
Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly reserved and, when issued in accordance with the provisions of this Warrant, will be validly issued, fully paid and
non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Warrant may be subject to restrictions on transfer under state and/or federal
securities laws and applicable agreements to which the Company or its security holders are parties. The Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates
for shares of Preferred Stock upon exercise of this Warrant shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of
shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 

(b) Due Authority. The execution and delivery by the Company of this Warrant and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company.
This Warrant: (1) is not inconsistent with the Company’s Charter or current bylaws; (2) subject to the accuracy of the Warrantholder’s representations in Section 10, does not contravene any law or governmental rule,
regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contact or other instrument to which it is a party or by which it is bound. This Warrant
constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its respective terms. 
 (c) Consents and
Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and
performance by the Company of its obligations under this Warrant, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time
required thereby. 
 (i) Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any
other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in full compliance with all federal and
state securities laws. Attached to this Warrant is a true and correct capitalization table of the Company. In accordance with the Company’s Charter, no shareholder of the Company has preemptive right to purchase new issuances of the
Company’s capital stock which right has not otherwise been waived in connection with the issuance of this Warrant. 
 (d) Other
Commitments to Register Securities. Except as set forth in this Warrant and the Investor Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act
any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (e) Exempt Transaction.
Subject to the accuracy of the Warrantholder’s representations in Section 10 (both at the time of the issuance of the Preferred Stock upon exercise of this Warrant and at the time of the issuance of the Common Stock upon conversion of
the Preferred Stock), the issuance of the Preferred Stock upon exercise of this Warrant, and the issuance of the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt from (i) the registration
requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 

 (f) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock
issuable upon the exercise of this Warrant, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the
Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 

 

	10.	REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

 This Warrant has been entered into
by the Company in reliance upon the following representations and covenants of the Warrantholder: 
 (a) Investment Purpose. The right
to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the Warrantholder’s rights contained herein are being acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder
has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 

(b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon exercise of this Warrant is not
registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant will be exempt from the registration and qualifications requirements thereof, and (ii) that the
Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 
 (c) Disposition of
Warrantholder’s Rights. In no event will the Warrantholder make a disposition of any of its rights to acquire Preferred Stock or Preferred Stock issuable upon exercise of such rights unless and until (i) it shall have notified the
Company of the proposed disposition, and (ii) if requested by the Company, it shall have furnished the Company with an opinion of counsel (which counsel may either be inside or outside counsel to the Warrantholder) reasonably satisfactory to
the Company and its counsel to the effect that (A) appropriate action necessary for compliance with the Act has been taken, or (B) an exemption from the registration requirements of the Act is available. Notwithstanding the foregoing, the
restrictions imposed upon the transferability of any of its rights to acquire Preferred Stock or Preferred Stock issuable on the exercise of such rights do not apply to transfers from the beneficial owner of any of the aforementioned securities to
its nominee or from such nominee to its beneficial owner, or to any transfers to an Affiliate (as such term is defined in the Act) of Warrantholder, and shall terminate as to any particular share of Preferred Stock when (1) such security shall
have been effectively registered under the Act and sold by the holder thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the Act, or (3) a letter
shall have been issued to the Warrantholder at its request by the staff of the SEC or a ruling shall have been issued to the Warrantholder at its request by the SEC stating that no action shall be recommended by such staff or taken by the SEC, as
the case may be, if such security is transferred without registration under the Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required.
Whenever the restrictions imposed hereunder shall terminate, as hereinabove provided, the Warrantholder or holder of a share of Preferred Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from the
Company, without expense to such holder, one or more new certificates for this Warrant or for such shares of Preferred Stock not bearing any restrictive legend. 

(d) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (e) Risk of No
Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), or file reports pursuant to Section
l5(d) of the 1934 Act, or if a registration statement covering the securities under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Warrant or (ii) the preferred Stock issuable
upon exercise of the right to purchase, it may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock
issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 

 (f) Accredited Investor. Warrantholder is an “accredited investor” within the
meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (g) Diligence. Warrantholder has had an
opportunity to discuss the Company’s business, management and financial affairs with its management and an opportunity to review the Company’s facilities. 
  

	11.	TRANSFERS AND LEGENDS. 

 (a) Subject to the terms and conditions contained in
Section 10, this Warrant and all rights hereunder are transferable in whole or in part by the Warrantholder and any successor transferee. The transfer shall be recorded on the books of the Company upon receipt by the Company of a notice of
transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. 

(b) Legend. The Preferred Stock (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the
following form: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SHARES UNDER THE ACT, OR PURSUANT TO RULE 144 UNDER
THE ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT (EXCEPT THAT AN OPINION SHALL NOT BE REQUIRED WITH RESPECT TO A TRANSFER WITHOUT CONSIDERATION TO AN AFFILIATE). THESE SECURITIES
HAVE NOT BEEN QUALIFIED UNDER THE LAWS OF ANY STATE, INCLUDING THE DEPARTMENT OF CORPORATIONS OF THE STATE OF CALIFORNIA, OR THE STATE AGENCIES OF DELAWARE. IN THE ABSENCE OF AN EXEMPTION FROM QUALIFICATION REQUIREMENT(S) UNDER APPLICABLE LAW, THE
ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL. 

Notwithstanding the foregoing, if the Preferred Stock has been held for one year from the later of the date of issuance by the Company or the
date such Preferred Stock was acquired from an “affiliate” of the Company (including periods of tacking, if any) and Warrantholder is not an “affiliate” of the Company (“affiliate” in each case, as defined in Rule 144
promulgated under the Act), then the Company hereby agrees to reissue the Shares without the legend above promptly following the date it receives written notice from Warrantholder requesting such removal and reissuance. 

 

	12.	MISCELLANEOUS. 

 (a) Effective Date. The provisions of this Warrant shall be
construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This Warrant shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by
suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and
where damages will not be readily ascertainable. 
 (c) Market Standoff. The Warrantholder shall be subject to the restrictions under
Section 1.14 of the Investor Rights Agreement to the same extent as the other parties thereto. 
 (d) No Impairment of Rights.
The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms
and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 

 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the
Company and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings reasonably incurred in enforcing this Warrant. For the purposes of this
Section 12(e), attorneys’ fees shall include without limitation fees reasonably incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of
any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or
enforce any judgment. 
 (f) Entire Agreement; Amendments. This Warrant constitute the entire agreement and understanding of the
parties hereto in respect of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter
hereof. None of the terms of this Warrant may be amended except by an instrument executed by each of the parties hereto. 
 (g) No
Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of
any such right or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter. 

(h) Survival. All agreements, representations and warranties contained in this Warrant or in any document delivered pursuant hereto
shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Warrant and the expiration or other termination of this Warrant. 

(i) Governing Law. This Warrant shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware,
excluding conflict of laws principles that would cause the application of laws of any other jurisdiction, 
 (j) Consent to Jurisdiction
and Venue. All judicial proceedings arising in or under or related to this Warrant may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant, each party
hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, California; (c) agrees not to assert any
defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Warrant, Nothing herein shall affect the right to serve process in any other
manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 (k)
Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to
apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF
ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. If this jury
waiver is for any reason unenforceable, all disputes shall be resolved by judicial reference under California Code of Civil Procedure Section 638. 

(l) Specific Performance. Warrantholder and Company agree that either may be irreparably damaged by any breach or threatened breach of
this Warrant. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Warrant by Warrantholder or Company, the other party shall, in addition to all other remedies, be entitled to seek a temporary or permanent injunction
and/or a decree for specific performance, in accordance with the provisions hereof. 

 (m) No Stockholder Rights. Prior to the exercise of this Warrant, the Warrantholder shall
not be entitled to vote or receive dividends or be deemed the holder of the Preferred Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be
construed to confer upon such holder, as such, any of the rights of a stockholder of the company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent
to any corporate action, whether upon any recapitalization, issuance of stock, reclassification of stock change of par value, consolidation, merger, conveyance, or otherwise, or to receive dividends or subscription rights or otherwise until this
Warrant shall have been exercised and the Preferred Stock purchasable upon the exercise hereof shall have become deliverable as provided herein. 

(n) Counterparts. This Warrant and any amendments, waivers, consents or supplements hereto may be executed in any number of
counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant to be executed by its officers
thereunto duly authorized as of the Effective Date. 
  

					
	 COMPANY:
		TRANSORAL PHARMACEUTICALS, INC.
			
			By:		  /s/ Illegible

			Title:		  

			
					 Attn: Tom Soloway, Chief Financial Officer

300 Tamal Plaza
 Corte Madera, CA 94925

		
	 WARRANTHOLDER:
		HERCULES TECHNOLOGY GROWTH
 CAPITAL, INC.

			
			By:		  /s/ Illegible

			Title:		Chief Legal Officer
			
					 Hercules Technology Growth Capital, Inc.

Attn: Kathy Conte
 525 University Ave, Suite 700

Palo Alto, CA 94301

			
			cc:		 Hercules Technology Growth Capital, Inc.

Attn: Chief Legal Officer
 525 University Avenue

Suite 700
 Palo Alto, CA 94301

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
TransOral Pharmaceuticals, Inc., hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology Growth Capital, Inc., to purchase [            ] shares of the
Series C Preferred Stock of TransOral Pharmaceuticals, Inc., pursuant to the terms of the Agreement, and further acknowledges that [            ] shares remain subject to purchase under the
terms of the Agreement. 
  

					
	COMPANY:		TRANSORAL PHARMACEUTICALS, INC.
			
			By:		  

			Title:		  

			Date:		  

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

					
	  

	(Please Print)				
		
	whose address is		  

	
	  

							
				
			Dated:		  
		

							
				
			Holder’s Signature:		  
		

							
				
			Holder’s Address:		  
		
			
			 		

 EXHIBIT IV 

JOINDER AGREEMENT 
 WHEREAS, the
undersigned Hercules Technology Growth Capital, Inc. (the “Joining Party”) and TransOral Pharmaceuticals, Inc., a Delaware corporation (the “Company”), have entered into a certain Loan and Security Agreement (the
“LSA”), dated as of April 13, 2006, and certain other related agreements contemplated thereby, pursuant to which, among other things, the Company will issue to the Joining Party one or more Warrants (the
“Warrant”) to purchase an aggregate of up to 434,783 shares of the Company’s Series C Preferred Stock, at an exercise price of $1.15 per share (the “Shares”); 

WHEREAS, the parties hereto desire the Joining Party to have certain registration rights with respect to the shares of Common Stock of the
Company issuable upon conversion of the Shares pursuant to Sections 1.02, 1.03 and 1.15 of that certain Investors’ Rights Agreement, dated as of October 25, 2005, among the Company and the other parties named therein, as the same may be
amended and/or restated from time to time (the “Rights Agreement”), and that the Joining Party be added to the Rights Agreement as parties thereto for the purpose of granting such registration rights; 

WHEREAS, Section 3.14 of the Rights Agreement allows the amendment or waiver of such Rights Agreement with the written consent of the
Company and the holders of at least 66 2/3% of the Registrable Securities, as defined therein, outstanding (the “Supermajority Holders”); and 

WHEREAS, Article V, Section E(3) of the Company’s Amended and Restated Certificate of Incorporation (the “Certificate”)
provides that the Supermajority Holders consent to those certain transactions as proposed in the Warrant and LSA. 
 NOW, THEREFORE, in consideration of the
promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged by the parties hereto, the parties hereby covenant and agree as follows: 

1. The shares of Common Stock of the Company issuable upon conversion of the Shares shall constitute “Registrable Securities,”
as such term is defined in Section 1.01(k) of the Rights Agreement, for all intents and purposes of the registration rights and related provisions and obligations set forth in Sections 1.01 through 1.16 inclusive and Section 3 of the
Rights Agreement. 
 2. The Joining party shall be treated for all purposes under Section 1.01 through 1.16 inclusive, and
Section 3 of the Rights Agreement as “Holders,” as such term is defined in Section 1.01(f) of the Rights Agreement. 

3. The Joining Party agrees to be bound by the terms and conditions of Sections 1.01 through 1.16 inclusive and Section 3 of the
Rights Agreement and shall succeed to and assume all of the rights and obligations of Holders of Registrable Securities for all intents and purposes of such Sections, provided that, the Joining Party shall not be deemed to possess any rights set
forth in Section 2 of the Rights Agreement. 
 4. All notices and other communications under the Rights Agreement shall be made
to the Joining Party at the address specified below and thereafter at such other address, notice of which is given in accordance with Section 3.04 of the Rights Agreement: 

Hercules Technology Growth Capital, Inc. 

Attn: Kathy Conte 
 525
University Ave, Suite 700 
 Palo Alto, CA 94301 

cc:   Hercules Technology Growth Capital, Inc. 

Attn: Chief Legal Officer 
 525
University Avenue 
 Suite 700 

Palo Alto, CA 94301 
 5.
The undersigned hereby consent to the sale and issuance by the Company of the Warrant, and hereby waive on behalf of themselves and all other such holders the right of first offer granted to such holders pursuant to Section 2.01 of the Rights
Agreement. The undersigned hereby further consents to and waives (i) any prior 

 
notice periods that may be contained in the Rights Agreement, or in any other documents or instrument that provides for prior notice of the sale and issuance of the Warrant pursuant to the LSA,
and (ii) any requirements as set forth in Article V, Section E(3) of the Certificate in connection with the LSA, the Warrant, or any transactions contemplated thereby. 

6. The Rights Agreement as modified herein shall remain in full force and effect as so modified 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. 
  

			
	TRANSORAL PHARMACEUTICALS, INC.
		
	By:		  

		
	Name:		  

		
	Title:		  

			
		
	INVESTORS:		

			
		
			See attached pages.

 Agreed and Accepted: 
  

			
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:		  

		
	Title:		  

			
	

		 75 Kneeland Street

Boston, Massachusetts 02111

617 275 0040

617 275 0039 fax
  

www.paratekpharm.com

 November 6, 2014 
 VIA
E-MAIL AND FIRST CLASS MAIL 
 Hercules Technology Growth Capital, Inc. 

525 University Ave, Suite 700 
 Palo Alto, CA 94301 

Attention: Kathy Conte 
 Copy to: Chief Legal Officer 

Re:             Notice of Special Dividend 

Ladies and Gentlemen: 
 Reference is hereby made to (i) that
certain Warrant Agreement (the “Agreement”), dated as of April 13, 2006, by and between Paratek Pharmaceuticals, Inc. (f/k/a Transcept Pharmaceuticals, Inc. or TransOral Pharmaceuticals, Inc.), a Delaware corporation (the
“Company”), and Hercules Technology Growth Capital, Inc., a Maryland corporation (“Hercules”), (ii) the Company’s press release dated October 14, 2014 and Forms 8-K filed with the U.S. Securities and Exchange
Commission (the “SEC”) on October 14, 2014 and October 20, 2014, each regarding the Company’s announcement of a special dividend (the “Dividend”) of an initial cash amount of $0.6674 per share (the “Cash
Amount”) and the right to receive certain Future Rights (as defined and described in the Company’s Form 8-K filed with the SEC on October 14, 2014), which Cash Amount was paid on October 29, 2014 (the “Payment Date”),
and (iii) the Company’s press release dated October 30, 2014 and Form 8-K filed with the SEC on October 31, 2014 regarding a reverse stock split of the Company’s common stock at a ratio of one new share for every twelve
shares outstanding (the “Reverse Stock Split”). 
 Pursuant to Section 8(d)(ii) and 8(f) of the Agreement, the Company hereby provides notice
to Hercules that the “Exercise price” (as defined in the Agreement) shall be adjusted from $6.806 to $73.6632 to take into account the effects of the Reverse Stock Split and Cash Amount paid pursuant to the Dividend ($6.806 per share less
the Cash Amount of $0.6674 per share = $6.1386 per share, and $6.1386 per share multiplied by 12 for the Reverse Stock Split equals $73.6632 per share). In addition, pursuant to Section 8(f) of the Agreement, the Company hereby provides notice
to Hercules that the number of shares of the Company’s common stock issuable upon exercise of the warrant pursuant to the Agreement shall be adjusted from 61,451 shares to 5,120 shares to take into account the effect of the Reverse Stock Split
(61,451 divided by 12). 
 To summarize, after giving effect to the Reverse Stock Split and the Dividend, Hercules has an outstanding warrant to purchase
5,120 shares of the Company’s common stock at an exercise price of $73.6632 per share, expiring on April 13, 2016. 

 Please do not hesitate to call me at (617) 275-0040 if you have any questions. 

Very truly yours, 
  

	
	/s/ Kathryn M. Boxmeyer
	
	Kathryn M. Boxmeyer
	Interim Chief Financial Officer
	Paratek Pharmaceuticals, Inc.EX-10.22

 EXHIBIT 10.22 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED. 
 PARATEK PHARMACEUTICALS, INC. 

WARRANT TO PURCHASE SERIES A PREFERRED STOCK 
  

			
	 No. PCW- 1_
		April 7, 2014

 VOID AFTER APRIL 7, 2021 

THIS CERTIFIES THAT, for value received, HBM Healthcare Investments
(Cayman) Ltd., with its principal office at Grand Cayman, Cayman Islands, or assigns (the “Holder”), is entitled to subscribe for and purchase from PARATEK PHARMACEUTICALS,
INC., a Delaware corporation, (the “Company”) the Exercise Shares at the Exercise Price (each subject to adjustment as provided herein). This Warrant is being issued as one of a series of warrants (the
“Warrants”) pursuant to the terms of the Senior Secured Note Purchase Agreement, dated March 7, 2014 by and among the Company and the lenders party thereto (the “Purchase Agreement”). Unless
indicated otherwise, the aggregate number of Exercise Shares that Holder may purchase by exercising this warrant is equal to the quotient of (A) the product of (i) 20% multiplied by (ii) the portion of the Remaining Shortfall (as
defined in the Purchase Agreement) purchased by the Holder pursuant to Section 2.1(b) of the Purchase Agreement, divided by (B) the Per Share Price, subject to adjustment pursuant to the terms hereof, including but not limited to
adjustments pursuant to Section 5, which equates to Forty Seven Thousand, Four Hundred and Thirty Eight (47,438). 
 1.
DEFINITIONS. Capitalized terms used but not defined herein shall have the meanings set forth in the Purchase Agreement. As used herein, the following terms shall have the following respective meanings: 

(a) “Exercise Period” shall mean the period commencing with the date hereof and ending seven (7) years
later. 
 (b) “Exercise Price” shall mean shall mean one cent ($0.01) per share, subject to adjustment
pursuant to Section 5 below. 
 (c) “Exercise Shares” shall mean shares of the Company’s Series A
Preferred Stock issuable upon exercise of this Warrant. 
 (d) “Per Share Price” shall mean the
Series A Original Issue Price (as such term is defined in the Company’s Amended and Restated Certificate of Incorporation, as may be amended from time to time, which as of the date hereof is $1.00). 

  
 1. 

 2. EXERCISE OF WARRANT. The rights
represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to
the Holder): 
 (a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of indebtedness; and 

(c) This Warrant. 
 Upon
the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and
delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. In the event that this Warrant is being exercised for less than all of the then-current number of Exercise Shares purchasable
hereunder, the Company shall, concurrently with the issuance by the Company of the number of Exercise Shares for which this Warrant is then being exercised, issue a new Warrant exercisable for the remaining number of Exercise Shares purchasable
hereunder. 
 The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant
shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that,
if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock
transfer books are open. 
 2.1 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one
Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant
(or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of Exercise Shares
computed using the following formula: 
  

							
							 X = Y (A-B)

            A

			
	Where		 	X =	  		the number of Exercise Shares to be issued to the Holder
			
			 	Y =	  		the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the date of such calculation)
			
			 	A =	  		the fair market value of one Exercise Share (at the date of such calculation)
			
			 	B =	  		Exercise Price (as adjusted to the date of such calculation)

  
 2. 

 For purposes of the above calculation, the fair market value of one Exercise Share shall be
determined by the Company’s Board of Directors in good faith; provided, however, that in the event that this Warrant is exercised pursuant to this Section 2.1 in connection with the Company’s initial public offering of its Common
Stock, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of Common Stock into which each Exercise Share is
convertible at the time of such exercise. 
 3. COVENANTS OF THE
COMPANY. 
 3.1 Covenants as to Exercise Shares. The Company covenants and agrees
that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to
the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of the series of equity securities
comprising the Exercise Shares to provide for the exercise of the rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of such series of the Company’s equity securities shall
not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of such series of the Company’s equity
securities to such number of shares as shall be sufficient for such purposes. 
 3.2 No Impairment. Except and to the extent as
waived or consented to by the Holder, the Company will not, by amendment of its Certificate of Incorporation, or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may be necessary or appropriate in order to protect the exercise rights of the Holder against impairment. 

3.3 Notices of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at least twenty (20) days prior to the date specified herein, a notice specifying the date on which
any such record is to be taken for the purpose of such dividend or distribution. 
 4. REPRESENTATIONS OF
HOLDER. 
 4.1 Acquisition of Warrant for Personal Account. The Holder represents and
warrants that it is acquiring the Warrant and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the
entire legal and beneficial interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

  
 3. 

 4.2 Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its
representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention. 
 (b) The Holder recognizes that the Warrant and the Exercise Shares must be
held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of the Company, or
to comply with any exemption from such registration. 
 (c) The Holder is aware that neither the Warrant nor the Exercise Shares may
be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the
resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been
satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 
 4.3 Disposition of
Warrant and Exercise Shares. 
 (a) The Holder further agrees not to make any disposition of all or any part of the
Warrant or Exercise Shares in any event unless and until: 
 (i) The Company shall have received a letter secured by the Holder from
the Securities and Exchange Commission stating that no action will be recommended to the Commission with respect to the proposed disposition; 

(ii) There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in
accordance with said registration statement; or 
 (iii) The Holder shall have notified the Company of the proposed disposition and
shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws. The Company agrees that it will not require an
opinion of counsel with respect to transactions under Rule 144 of the Securities Act of 1933, as amended, except in unusual circumstances. 

  
 4. 

 (b) The Holder understands and agrees that all certificates evidencing the shares to be
issued to the Holder may bear the following legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 4.4 Accredited Investor Status. The Holder is an “accredited investor”
as defined in Regulation D promulgated under the Act. 
 5. ADJUSTMENT OF EXERCISE
PRICE AND NUMBER OF EXERCISE SHARES. 

5.1 Changes in Securities. In the event of changes in the series of equity securities of the Company comprising the Exercise Shares by
reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of Exercise Shares available under the Warrant in the
aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been
exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment. For purposes of this Section 5, the “Aggregate Exercise Price” shall mean the aggregate Exercise
Price payable in connection with the exercise in full of this Warrant. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

5.2 Automatic Conversion. Upon the automatic conversion of all outstanding shares of the series of equity securities comprising the
Exercise Shares in accordance with the Company’s Certificate of Incorporation, this Warrant shall become exercisable for that number of shares of Common Stock of the Company into which the Exercise Shares would then be convertible, so long as
such shares, if this Warrant had been exercised prior to such offering, would have been converted into shares of the Company’s Common Stock pursuant to the Company’s Certificate of Incorporation. In such case, all references to
“Exercise Shares” shall mean shares of the Company’s Common Stock issuable upon exercise of this Warrant, as appropriate. 

6. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of
this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) to be issued upon exercise of this Warrant shall be aggregated for purposes of determining whether the exercise would result in the issuance
of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal
to the product resulting from multiplying the then current fair market value of one Exercise Share by such fraction. 

  
 5. 

 7. MARKET STAND-OFF AGREEMENT.
Holder hereby agrees that Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock
(or other securities) of the Company held by Holder (other than those included in the registration) during the 180-day period following the effective date of the initial public offering (or such longer period, not to exceed 34 days after the
expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation) as the underwriters or the Company
shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation); provided, that, all officers and directors of the Company and holders of at least one percent (1%) of
the Company’s voting securities are bound by and have entered into similar agreements. Holder further agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the managing underwriters that are
consistent with the foregoing or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Holder shall provide, within
ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under
the Securities Act. The obligations described in this Section 8 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration
relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other
securities) until the end of such period. Holder agrees that any transferee of the Warrant (or other securities) of the Company held by Holder shall be bound by this Section 7. The underwriters of the Company’s stock are intended third
party beneficiaries of this Section 7 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

8. AUTOMATIC EXERCISE. Any portion of this Warrant that has not been earlier exercised prior to the
expiration of this Warrant shall be automatically exercised, without any required action by Holder, on a cashless basis as set forth in Section 2.1 immediately prior to the expiration of this Warrant. In the event of a Deemed Liquidation Event
(as defined in the Company’s Certificate of Incorporation as in effect on the date hereof), the Company shall notify the Holder in writing at least twenty (20) days prior to the consummation of such event or transaction and,
notwithstanding anything to the contrary herein, the Warrant shall be exercisable during such ten (20) day period. Unless this Warrant has been earlier exercised at or immediately prior to the closing of such Deemed Liquidation Event, this
Warrant (or any portion thereof that hasn’t been exercised already) shall be automatically exercised, without any required action by Holder, on a cashless basis as set forth in Section 2.1 with such cashless exercise effective and
conditioned upon the consummation of such Deemed Liquidation Event. 
 9. NO STOCKHOLDER
RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. 

10. TRANSFER OF WARRANT. Subject to applicable laws and the restriction on transfer set
forth on the first page of this Warrant, this Warrant and all rights hereunder are 

  
 6. 

 
transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. The
transferee shall sign an investment letter in form and substance satisfactory to the Company. 
 11. LOST,
STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an
original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

12. AMENDMENT. Any term of this Warrant may be amended or waived with the written consent of the Company and Holders of
at least a majority-in-interest of the outstanding Warrants, provided that all Warrants are similarly affected. Upon the effectuation of such amendment or waiver in conformance with this Section 11, the Company shall promptly give written
notice thereof to the record holders of the Warrants who have not previously consented thereto in writing. 
 13.
NOTICES. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if
sent during normal business hours of the recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day
after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at Centennial
Towers, 3rd Floor, 2454 West Bay Road, Grand Cayman, Cayman Islands or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto; provided, however, only a
nationally recognized overnight courier shall be used to effectuate the delivery of any notices to addresses outside the United States. 

14. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms
and conditions contained herein. 
 15. GOVERNING LAW. This Warrant and all rights, obligations and
liabilities hereunder shall be governed by and construed under the laws of the State of Delaware as applied to agreements among Delaware residents, made and to be performed entirely within the State of Delaware without giving effect to conflicts of
laws principles. 
 16. VALIDITY. If any provision of this Warrant shall be judicially determined to be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

[Signature Page Follows] 

  
 7. 

 IN WITNESS WHEREOF, the Company has caused
this Warrant to be executed by its duly authorized officer as of the date first written above. 
  

			
	 PARATEK PHARMACEUTICALS, INC.

		
	 By:
		   /s/ Dennis Molnar

			Dennis Molnar
			Chief Executive Officer
		
	 Address:
		  

 PARATEK PHARMACEUTICALS, INC. 

WARRANT TO PURCHASE SERIES A PREFERRED STOCK –
SIGNATURE PAGE 

 NOTICE OF EXERCISE 

TO: PARATEK PHARMACEUTICALS, INC. 

(1)  ̈ The undersigned hereby elects to purchase
            shares of             (the “Exercise Shares”) of Paratek Pharmaceuticals, Inc. (the
“Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

 ̈ The undersigned hereby elects to purchase
            shares of             (the “Exercise Shares”) of Paratek Pharmaceuticals, Inc. (the
“Company”) pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2) Please issue a certificate or certificates representing said Exercise Shares in the name of the undersigned or in such other name
as is specified below: 
  

	
	  

	(Name)
	
	  

	  

	(Address)

 (3) The undersigned represents that (i) the aforesaid Exercise Shares
are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares;
(ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company;
(iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting
the undersigned’s own interests; (iv) the undersigned understands that Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such
securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the
aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions
for use of the Rule is the availability of current information to the public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any
disposition of all or any part of the aforesaid shares of Exercise Shares unless and until  

  
 1. 

 
there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or, if
reasonably requested by the Company, the undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 

 

			
	 		  

	 (Date)
		(Signature)
		
			  

			(Print name)

  
 2. 

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase
shares.) 
 FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby
are hereby assigned to 
  

			
	Name:		  

			
	 (Please Print)

		
	Address:		  

			
	 (Please Print)

	
	 Dated:
                    , 20    

	
	 Holder’s

			
	Signature:		  

	
	 Holder’s

			
	Address:		  

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant. 

  
 3. 

 October 6 , 2014 

HBM Healthcare Investments (Cayman) Ltd. 
 Governors Square,
Suite #4-212-2 
 23 Lime Tree Bay Avenue 
 West Bay 

Grand Cayman, Cayman Islands 
 Omega Fund III, L.P. 

1 Royal Plaza 
 Royal Avenue 

St. Peter Port 
 Guernsey 

K/S Danish BioVenture 
 545 Boylston Street 

Suite 802 
 Boston, Massachusetts 02116 

Transcept Pharmaceuticals, Inc. 
 1003 W. Cutting Blvd., Suite
#110 
 Point Richmond, California 94804 
 Dear Ladies and
Gentlemen: 
 Each of HBM Healthcare Investments (Cayman) Ltd., Omega Fund III, L.P. and K/S Danish BioVenture is a holder of a warrant,
dated April 7, 2014, April 7, 2014 and April 18, 2014, respectively, to purchase shares of Series A Preferred Stock, $0.001 par value per share (“Series A Preferred Stock”), (collectively, the “Series A
Preferred Warrants”) of Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 
 As you know,
the Corporation is a party to that certain Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014, by and among Transcept Pharmaceuticals, Inc., a Delaware corporation (“Tigris”), Tigris Merger Sub, Inc., a
Delaware corporation and a wholly owned subsidiary of Tigris (“Merger Sub”), Tigris Acquisition Sub, LLC, a Delaware limited liability company, and the Corporation (the “Merger Agreement”), pursuant to which Merger
Sub would merge with and into the Corporation with the Corporation surviving and the stockholders of the Corporation receiving 0.810 shares of Tigris’ common stock, $0.001 par value per share (“Tigris Common Stock”), subject to
adjustment to account for Tigris’ proposed 12:1 reverse stock split (the “Exchange Ratio”), for every one share of the Corporation’s common stock, $0.001 par value per share (“Common Stock”), issued and
outstanding and held by them immediately prior to the Merger, upon the terms and subject to the conditions set forth therein. 

 Pursuant to Section 5.5(c) of the Merger Agreement, at the Effective Time (as defined in the
Merger Agreement), each Series A Preferred Warrant that is outstanding and unexercised immediately prior to the Effective Time shall become converted into and become a warrant to purchase Tigris Common Stock and Tigris shall assume each such Series
A Preferred Warrant in accordance with its terms. In addition, pursuant to Section 5.5(c) of the Merger Agreement, all rights with respect to Common Stock or Series A Preferred Stock under the Series A Preferred Warrants assumed by Tigris shall
thereupon be converted into rights with respect to Tigris Common Stock, and, accordingly, from and after the Effective Time: (i) each Series A Preferred Warrant assumed by Tigris may be exercised solely for shares of Tigris Common Stock;
(ii) the number of shares of Tigris Common Stock subject to each Series A Preferred Warrant assumed by Tigris shall be determined by multiplying (A) the number of shares of Common Stock issuable upon conversion of the shares of Series A
Preferred Stock issuable upon exercise of the Series A Preferred Warrant that were subject to such Series A Preferred Warrant immediately prior to the Effective Time by (B) the Exchange Ratio and rounding the resulting number down to the
nearest whole number of shares of Tigris Common Stock; (iii) the per share exercise price for the Tigris Common Stock issuable upon exercise of each Series A Preferred Warrant assumed by Tigris shall be determined by dividing the per share
exercise price of Series A Preferred Stock subject to such Series A Preferred Warrant, as in effect immediately prior to the Effective Time, by the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent; and
(iv) any restriction on any Series A Preferred Warrant assumed by Tigris shall continue in full force and effect and the terms and other provisions of such Series A Preferred Warrant shall otherwise remain unchanged. 

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Corporation and each of HBM Healthcare
Investments (Cayman) Ltd., Omega Fund III, L.P. and K/S Danish BioVenture hereby agree that, contingent upon and effective at the Effective Time, each Series A Preferred Warrant shall be converted into a warrant to purchase Tigris Common Stock and
shall be assumed by Tigris upon the terms and subject to the conditions set forth in the Merger Agreement. Each of HBM Healthcare Investments (Cayman) Ltd., Omega Fund III, L.P. and K/S Danish BioVenture hereby further agree not to exercise their
respective Series A Preferred Warrant prior to the Effective Time unless and until the Merger Agreement is terminated in accordance with its terms. 

This letter agreement may be executed in separate counterparts, each of such counterparts shall for all purposes be deemed to be an original
and all such counterparts shall together constitute but one and the same instrument. 
 [Remainder of Page Intentionally Blank] 

  
 - 2 - 

 If you agree with the foregoing, please sign and return one copy of this letter to the
Corporation. 
  

			
	Very truly yours,
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:		   /s/ Evan Loh

	Name:		Evan Loh, MD
	Title:		President
			Paratek Pharmaceuticals

 CONFIRMED AND AGREED 
 AS
OF THE DATE WRITTEN ABOVE: 
 HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. 
  

			
	By:		   /s/ Jean Marc Lesieur

	Name:		Jean Marc Lesieur
	Title:		Director

  

			
	OMEGA FUND III, L.P.
		
	By:		OMEGA FUND III GP, LP
		
	By:		OMEGA FUND III GP, LTD.
		
	By:		  

	Name:		
	Title:		

  

			
	K/S DANISH BIOVENTURE
		
	By:    		DANISH BIOVENTURE GENERAL PARTNER APS

			
		
	By:		  

	Name:		
	Title:		

  

			
	TRANSCEPT PHARMACEUTICALS, INC.
		
	By:		  

	Name:		
	Title:		

  
 - 3 - 

 If you agree with the foregoing, please sign and return one copy of this letter to the If you
agree with the foregoing, please sign and return one copy of this letter to the Corporation. 
  

			
	Very truly yours,
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:		   /s/ Evan Loh

	Name:		Evan Loh, MD
	Title:		President
			Paratek Pharmaceuticals

 CONFIRMED AND AGREED 
 AS
OF THE DATE WRITTEN ABOVE: 
 HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. 
  

			
	By:		  

	Name:		Jean Marc Lesieur
	Title:		Director

  

			
	OMEGA FUND III, L.P.
		
	By:		OMEGA FUND III GP, LP
		
	By:		OMEGA FUND III GP, LTD.
		
	By:		   /s/ David Bolton

	Name:		David Bolton
	Title:		Director

  

			
	K/S DANISH BIOVENTURE
		
	By:    		DANISH BIOVENTURE GENERAL PARTNER APS

			
		
	By:		  

	Name:		
	Title:		

  

			
	TRANSCEPT PHARMACEUTICALS, INC.
		
	By:		  

	Name:		
	Title:		

  
 - 3 - 

 If you agree with the foregoing, please sign and return one copy of this letter to the
Corporation. 
  

			
	Very truly yours,
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:		   /s/ Evan Loh

	Name:		Evan Loh, MD
	Title:		President
			Paratek Pharmaceuticals

 CONFIRMED AND AGREED 
 AS
OF THE DATE WRITTEN ABOVE: 
 HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. 
  

			
	By:		  

	Name:		Jean Marc Lesieur
	Title:		Director

  

			
	OMEGA FUND III, L.P.
		
	By:		OMEGA FUND III GP, LP
		
	By:		OMEGA FUND III GP, LTD.
		
	By:		  

	Name:		
	Title:		

  

			
	K/S DANISH BIOVENTURE
		
	By:    		DANISH BIOVENTURE GENERAL PARTNER APS

			
		
	By:		   /s/ Richard Lim

	Name:		Richard Lim
	Title:		Director

  

			
	TRANSCEPT PHARMACEUTICALS, INC.
		
	By:		  

	Name:		
	Title:		

  
 - 3 - 

 If you agree with the foregoing, please sign and return one copy of this letter to the
Corporation. 
  

			
	Very truly yours,
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:		   /s/ Evan Loh

	Name:		Evan Loh, MD
	Title:		President
			Paratek Pharmaceuticals

  

			
	CONFIRMED AND AGREED
	AS OF THE DATE WRITTEN ABOVE:
	
	HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.

  

			
	By:		  

	Name:		Jean Marc Lesieur
	Title:		Director

  

			
	OMEGA FUND III, L.P.
		
	By:		OMEGA FUND III GP, LP
		
	By:		OMEGA FUND III GP, LTD.
		
	By:		  

	Name:		
	Title:		

  

			
	K/S DANISH BIOVENTURE
		
	By:    		DANISH BIOVENTURE GENERAL PARTNER APS

  

			
	By:		  

	Name:		
	Title:		

  

			
	TRANSCEPT PHARMACEUTICALS, INC.
		
	By:		   /s/ Glenn A. Oclassen

	Name:		Glenn A. Oclassen
	Title:		Chmn/CEO

  
 - 3 - 

			
	

		 75 Kneeland Street

Boston, Massachusetts 02111
 617 275
0040
 617 275 0039 fax
  

www.paratekpharm.com

 November 7, 2014 

HBM Healthcare Investments (Cayman) Ltd. 
 Attn: Matthias Fehr
and Jean-Marc Lesieur 
 Governors Square, Suite #4-212-2 
 23
Lime Tree Bay Avenue 
 West Bay 
 Grand Cayman, Cayman Islands

 Dear Mr. Fehr and Mr. Lesieur: 

This letter is to notify you that the merger of Tigris Merger Sub, Inc. (“Merger Sub”) with and into Paratek Pharmaceuticals, Inc.
(“Old Paratek”) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014, by and among Transcept Pharmaceuticals, Inc. (“New Paratek”), Merger Sub, Tigris Acquisition Sub, LLC and
Old Paratek (the “Merger Agreement”) became effective on October 30, 2014. New Paratek was subsequently renamed “Paratek Pharmaceuticals, Inc.” Under the terms of the Merger Agreement, each outstanding share of common stock
of Old Paratek was exchanged for 0.0675 of a share of New Paratek common stock. 
 Pursuant to the Merger Agreement and that certain letter
agreement, dated October 6, 2014, by and among Old Paratek, New Paratek, HBM Healthcare Investments (Cayman) Ltd. (“HBM”), Omega Fund III, L.P. and K/S Danish BioVenture, HBM’s warrant, dated April 7, 2014, to purchase
47,438 shares of Series A Preferred Stock of Old Paratek at an exercise price of $0.01 per share has been converted into and become a warrant to purchase 3,202 shares of New Paratek common stock at an exercise price of $0.15 per share. Pursuant to
the Merger Agreement, any restriction on such warrant shall continue in full force and effect and the terms and other provisions of such warrant shall otherwise remain unchanged. 

If you have any questions regarding the warrant, please contact Kathryn M. Boxmeyer, our Interim Chief Financial Officer, at
(617) 275-0040. 
  

			
	Very truly yours,
	
	PARATEK PHARMACEUTICALS, INC.
	(f/k/a Transcept Pharmaceuticals, Inc.)
		
	By:		   /s/ Evan Loh

			
	Name:		Evan Loh
	Title:		President and Chief Medical Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]